Last week, ClarivateTM Analytics released the 2019 update of its Journal Citation Reports©, including the much anticipated 2018 impact factor. EASL’s flagship monthly journal, the Journal of Hepatology achieved unprecedented results with a 2018 impact factor of 18.946, up from the 2017 score of 14.911.
The ranking reveals that the Journal of Hepatology continues to surge ahead with an impressive 26% increase in one year and a total increase of more than 50% in the past two years. To date, the 2018 score is the highest the Journal of Hepatology has achieved.
“I am delighted to see that the Journal of Hepatology has attained first position amongst the specialist Hepatology Journals, increasing its impact factor by 26% to 18.946 and reducing the gap between it and the top Gastroenterology journal down to 0.28 points. I acknowledge gratefully the architects of this huge success; the amazing Senior Editors, the incredible Journal office, the unrelenting support of EASL, the brilliant Editorial team, the untiring peer reviewers and the very innovative authors. It is particularly pleasing to see that this increase in the impact factor is associated with improved quality of the Journal in terms of larger numbers of original papers being cited more often, its turnaround time, production schedules, geopolitical footprint and readability,” said Prof. Rajiv Jalan, Editor-in-Chief of the Journal of Hepatology.
The record high score together with similar increases in other metrics like CiteScore and SCImago Journal Rank reaffirms the continued commitment of EASL, The Home of Hepatology™ to provide the scientific community with a high-quality publication that delivers impactful content in liver research.
“The EASL Governing Board congratulates the Editorial team, the Editorial board and the Journal office on their amazing achievement in delivering the highest ever impact factor for the Journal of Hepatology. The continued innovation in the journal has meant it now attracts some of the most important papers in the literature which have a major impact on research and clinical practice. The Journal of Hepatology is an EASL flagship, and thanks to the hard work of Rajiv Jalan and his team our journal has well and truly established itself in the top tier of academic publishing,” said Prof. Phil Newsome, Secretary General of EASL.
An impact factor is a measure of a journal’s significance in an academic field. It considers the frequency with which the average article in a journal is cited in a given year. This data helps indicate a journal’s relative importance when compared to other publications in the same field. The Journal of Hepatology publishes 12 issues a year and covers a wide variety of topics in clinical and basic research within the field.
About the Journal of Hepatology
The Journal of Hepatology is a monthly, English language, peer-reviewed journal. First published in 1985 as the official journal of EASL, it provides an international forum for the publication of original articles, reviews and letters to the Editor describing basic laboratory, translational, and clinical investigations in hepatology. All articles undergo a rigorous peer review and are selected based on the originality of the findings, the superior quality of the work described, and the clarity of presentation. http://www.journal-of-hepatology.eu
This year the Journal of Hepatology achieved exceptional results with a 2018 impact factor of 18.95, the highest the Journal has achieved, and with more than 2’600’000 downloads in 2018, it is firmly established as one of the premier publications in the field of Gastroenterology and Hepatology. Last year 46% of submissions originated from Asia, 13% from the USA and 33% from Europe, indicating the truly international nature of the Journal.
About The European Association for the Study of the Liver (EASL) – The Home of Hepatology
Since its foundation in 1966, this not-for-profit organization has grown to over 4,000 members from all over the world, including many of the leading hepatologists in Europe and beyond. EASL is the leading liver association in Europe, having evolved into a major European association with international influence, and with an impressive track record in promoting research in liver disease, supporting wider education and promoting changes in European liver policy. https://www.easl.eu
Clarivate™ Analytics accelerates the pace of innovation by providing trusted insights and analytics to customers around the world, enabling them to discover, protect and commercialize new ideas faster. Formerly the Intellectual Property and Science business of Thomson Reuters, it owns and operates a collection of leading subscription-based businesses focused on scientific and academic research, patent analytics and regulatory standards, pharmaceutical and biotech intelligence, trademark protection, domain brand protection and intellectual property management. Clarivate™ Analytics is now an independent company with over 4,000 employees, operating in more than 100 countries and owns well-known brands that include Web of Science™, Cortellis™, Derwent™, CompuMark™, MarkMonitor® and Techstreet™, among others. For more information, please visit clarivate.com.